German conglomerate Beiersdorf AG acquired a majority stake in Belgian life science company brand S-Biomedic NV, considered a pioneer in skin microbiome research.
WHO: S-Biomedic is a Belgium-based life science company founded by Veronika Oudova and Bernhard Paetzold in 2014. The company researches and develops active ingredients for cosmetics products using living skin bacteria, exploring the skin microbiome's unexploited cosmetic and therapeutic potential. In this field, S-Biomedic has developed a program focusing on acne, and two early-stage concept development programs have been initiated focusing on aging and dandruff.
Beiersdorf AG is a leading provider of innovative, high-quality skincare products and has over 135 years of experience in this market segment. Its product portfolio comprises strong, international leading skin and body care brands including Nivea, Eucerin, Hansaplast/Elastoplast, La Prairie, Labello, Aquaphor, Florena, 8×4, Hidrofugal, atrix, SLEK, and Maestro.
WHY: Beiersdorf invested in S-Biomedic in 2018 as part of its corporate venture capital activities. Following years of successful cooperation, the collaboration will now become even closer. S-Biomedic will complement the company's own research activities in the microbiome field.
IN THEIR OWN WORDS: "As skin care experts, research has been at the heart of what we have been doing for 140 years. Therefore, the acquisition of S-Biomedic is an ideal strategic fit to drive our innovation power even further in line with our C.A.R.E.+ strategy. Together with the pioneers of S-Biomedic we are taking skin care to the next level and will foster the development of solutions for unmet consumer needs," emphasizes Dr. Gitta Neufang, Senior Vice President of Research & Development at Beiersdorf.
"We are pleased to welcome S-Biomedic and its dedicated team to the Beiersdorf Group to join forces in this dynamic and highly promising research area. The advances of S-Biomedic in biomedical research complement our own efforts in this field and open the door to develop products that work in harmony with the natural skin processes," adds Jörn Hendrik Reuter, Manager Microbiome Accelerator at Beiersdorf.
"Our vision since 2014 when we started S-Biomedic has been to build and promote skin microbiome technologies and make them to the new frontier in skin health. I am very excited that together with the team we have achieved a very important milestone on that journey. By joining Beiersdorf our novel approach has its path to consumers all over the world," says Veronika Oudova, CEO of S-Biomedic.
DETAILS:
